Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may decrease lymphedema risk in breast cancer patients
Crossref DOI link: https://doi.org/10.1007/s00520-018-4113-5
Published Online: 2018-02-21
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Altundag, Kadri
Text and Data Mining valid from 2018-02-21
Article History
Received: 15 November 2017
Accepted: 11 February 2018
First Online: 21 February 2018
Compliance with ethical standards
:
: The author declares that he has no conflict of interest.